D
David A. Cooper
Researcher at Pfizer
Publications - 965
Citations - 81765
David A. Cooper is an academic researcher from Pfizer. The author has contributed to research in topics: Acquired immunodeficiency syndrome (AIDS) & Viral load. The author has an hindex of 117, co-authored 903 publications receiving 69249 citations. Previous affiliations of David A. Cooper include Boston Children's Hospital & National Institutes of Health.
Papers
More filters
Journal ArticleDOI
The impact of HIV therapy on co-infection with hepatitis B and hepatitis C viruses.
Gregory J. Dore,David A. Cooper +1 more
TL;DR: The dual anti-HIV and anti-hepatitis B activity of several established and emerging therapeutic agents provides the opportunity to both restore immune function and prevent liver disease progression in people with HIV-hePatitis B virus co-infection.
Journal ArticleDOI
Antibodies to the human immunodeficiency virus in needles and syringes used by intravenous drug abusers.
TL;DR: This method of monitoring exchanged needles‐and‐syringes is suggested as a means to evaluate measures that are designed to reduce the transmission of HIV among intravenous drug abusers to stem the spread of HIV infection.
Journal ArticleDOI
The neurological features of early and 'latent' human immunodeficiency virus infection.
Bruce J. Brew,M. Perdices,P. Darveniza,Paul Edwards,B. Whyte,W. J. Burke,Raymond Garrick,D. J. O'sullivan,Ronald Penny,David A. Cooper +9 more
TL;DR: The range of abnormalities that may be seen at seroconversion is extended and the presence of a non-progressive cognitive deficit occurring in the latent phase of HIV infection is documents.
Journal ArticleDOI
Efficacy and safety of maraviroc vs. efavirenz in treatment-naive patients with HIV-1: 5-year findings
David A. Cooper,Jayvant Heera,Prudence Ive,Mariette E. Botes,Edwin DeJesus,Robert Burnside,Nathan Clumeck,Sharon Walmsley,Adriano Lazzarin,Geoffrey Mukwaya,Michael S. Saag,Elna van der Ryst +11 more
TL;DR: Maraviroc maintained similar long-term antiviral efficacy to efavirenz over 5 years in treatment-naive patients with CCR5-tropic HIV-1, and was generally well tolerated with no unexpected safety findings or evidence of long- term safety concerns.
Journal ArticleDOI
Outcomes of a Noninferiority Randomised Controlled Trial of Surgery for Men with Urodynamic Stress Incontinence After Prostate Surgery (MASTER)
Paul Abrams,Lynda Constable,David A. Cooper,Graeme MacLennan,Marcus J. Drake,Marcus J. Drake,Christopher Harding,Christopher Harding,Anthony R. Mundy,Kirsty McCormack,Alison McDonald,John Norrie,Craig R Ramsay,Rebecca Smith,Nikki Cotterill,Nikki Cotterill,Mary Kilonzo,Cathryn Glazener +17 more
TL;DR: In this paper, the outcomes of surgery in men with bothersome urodynamic SUI after prostate surgery were compared with those who have an artificial urinary sphincter (AUS).